Difference between revisions of "Cytokeratin 19"
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
*[[Adamantinoma]]. | *[[Adamantinoma]]. | ||
*[[Yolk sac tumour]].<ref>{{Cite journal | last1 = Bremmer | first1 = F. | last2 = Ströbel | first2 = P. | last3 = Hubertus | first3 = H. | last4 = Strecker | first4 = J. | last5 = Gaisa | first5 = N. | last6 = Strauß | first6 = A. | last7 = Schweyer | first7 = S. | last8 = Radzun | first8 = H-J. | last9 = Behnes | first9 = C-L | title = CK19 is a sensitive marker for yolk sac tumours of the testis. | journal = Diagnostic Pathology | volume = 10 | issue = 7 | pages = | month = | year = 2015 | doi = 10.1186/s13000-015-0243-y | PMID = | url = www.diagnosticpathology.org/content/10/1/7Cached }}</ref> | *[[Yolk sac tumour]].<ref>{{Cite journal | last1 = Bremmer | first1 = F. | last2 = Ströbel | first2 = P. | last3 = Hubertus | first3 = H. | last4 = Strecker | first4 = J. | last5 = Gaisa | first5 = N. | last6 = Strauß | first6 = A. | last7 = Schweyer | first7 = S. | last8 = Radzun | first8 = H-J. | last9 = Behnes | first9 = C-L | title = CK19 is a sensitive marker for yolk sac tumours of the testis. | journal = Diagnostic Pathology | volume = 10 | issue = 7 | pages = | month = | year = 2015 | doi = 10.1186/s13000-015-0243-y | PMID = | url = www.diagnosticpathology.org/content/10/1/7Cached }}</ref> | ||
*Breast carcinoma - common (~91%).<ref name=pmid25453845 | *Breast carcinoma - common (~91%).<ref name=pmid25453845/> | ||
*[[Lung adenocarcinoma]] (~95%).<ref name=pmid25453845></ref> | *[[Lung adenocarcinoma]] (~95%).<ref name=pmid25453845>{{Cite journal | last1 = Masai | first1 = K. | last2 = Nakagawa | first2 = K. | last3 = Yoshida | first3 = A. | last4 = Sakurai | first4 = H. | last5 = Watanabe | first5 = S. | last6 = Asamura | first6 = H. | last7 = Tsuta | first7 = K. | title = Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases. | journal = Lung Cancer | volume = 86 | issue = 3 | pages = 318-23 | month = Dec | year = 2014 | doi = 10.1016/j.lungcan.2014.09.018 | PMID = 25453845 }}</ref> | ||
==Negative== | ==Negative== | ||
Revision as of 21:40, 20 August 2015
Cytokeratin 19, abbreviated CK19, is a commonly available keratin.
Positive
- Thyroid.[1]
- Gastrointestinal tract.[1]
- Pancreas.[1]
- Cholangiocarcinoma.
- Salivary gland - marks luminal cells.
- Adamantinoma.
- Yolk sac tumour.[2]
- Breast carcinoma - common (~91%).[3]
- Lung adenocarcinoma (~95%).[3]
Negative
See also
References
- ↑ 1.0 1.1 1.2 Jain, R.; Fischer, S.; Serra, S.; Chetty, R. (Jan 2010). "The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver.". Appl Immunohistochem Mol Morphol 18 (1): 9-15. doi:10.1097/PAI.0b013e3181ad36ea. PMID 19956064.
- ↑ Bremmer, F.; Ströbel, P.; Hubertus, H.; Strecker, J.; Gaisa, N.; Strauß, A.; Schweyer, S.; Radzun, H-J. et al. (2015). [www.diagnosticpathology.org/content/10/1/7Cached "CK19 is a sensitive marker for yolk sac tumours of the testis."]. Diagnostic Pathology 10 (7). doi:10.1186/s13000-015-0243-y. www.diagnosticpathology.org/content/10/1/7Cached.
- ↑ 3.0 3.1 Masai, K.; Nakagawa, K.; Yoshida, A.; Sakurai, H.; Watanabe, S.; Asamura, H.; Tsuta, K. (Dec 2014). "Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases.". Lung Cancer 86 (3): 318-23. doi:10.1016/j.lungcan.2014.09.018. PMID 25453845.